Dr. Jack Cush – Rheumatology Round-Up at ACR 17
Dr. Arthur Kavanaugh: ACR Wrap-Up
Dr. Philip Robinson: Osteoarthritis and Inflammation
Like this #ACR17 and we’re now in an osteoporosis crisis pic.twitter.com/raom7N3i2r
— Nicola Garrett (@nicola_garrett) November 6, 2017
May interest those tweeting @ #ACR17:
What healthcare workers can learn frm #twitter
by @gmacscotlandhttps://t.co/JmmmReieCd#socialmedia pic.twitter.com/O8qwuDSmQK— Dr Ai Lyn Tan (@DrAiLynTan) November 7, 2017
#GAMECHANGER. Failure of RA guidelines. 67% of MTX mono fail. Combo DMARDs or scMTX is better #acr17 @rheumnow #443 pic.twitter.com/q4P0fk460V
— Janet (@Janetbirdope) November 8, 2017
I think that is a simplistic view, skills, knowledge and unknowns probably play a role in my view #ACR17 @RheumNow https://t.co/acvvhzFKcn
— Philip Robinson (@philipcrobinson) November 8, 2017
#GAMECHANGER. More remission in early RA CATCH cohort over time despite less biologic use. ?why #acr17 @rheumnow #1814 pic.twitter.com/QpDAZ2LJ08
— Janet (@Janetbirdope) November 8, 2017
No difference in lung safety of Abatacept and TNFI and one study of more ILD with IFX vs ABA #137. #acr17 @rheumnow #526 pic.twitter.com/ugYBF7THKa
— Janet (@Janetbirdope) November 8, 2017
Thank you everyone at @ACRheum I had a blast and the meeting, as always, was well worth coming all this way for. Keep up the good work, hope to see you all in Chicago next year #ACR17
— Philip Robinson (@philipcrobinson) November 8, 2017
RheumNow coverage of ACR17 Annual mtg is sponsored by Eli Lilly & Co. All content chosen by RheumNow Faculty https://t.co/WEPgNIaiaB
— Dr. John Cush (@RheumNow) November 8, 2017
Great showing from young investigators and NIH/foundation representatives! #ACR17 #SCSatACR https://t.co/HgcF0Xcgb7
— Jeff Sparks (@jeffsparks) November 8, 2017
Come do Orange Theory w/ me! High intensity interval training may improve fatigue in PsA pts. #ACR17 @RheumNow #2968 https://t.co/il89TsLIwY pic.twitter.com/smAg512J8Z
— Dr. Rachel Tate (@uptoTate) November 8, 2017
Renal Tx in SLE with ESRD have reduced mortality esp CVD and cancer, reassuring data #ACR17 @RheumNow #2921
— Ian N Bruce (@Lupusdoc) November 8, 2017
CCL21 – a potential marker for SSc-PAH risk prediction and PAH progression. #ACR17 @RheumNow #2980 https://t.co/2YuAQHjr17
— Dr. Rachel Tate (@uptoTate) November 8, 2017
JHU experience with Rheumatic irAEs: inflammatory arthritis features differ by ICI regimen #2902 @cappelliMD @RheumNow #ACR17
— Cassandra Calabrese (@CCalabreseDO) November 8, 2017
#GAMECHANGER. Steroids cost more in rheumatic diseases; dose dependent Limit or reduce dose. #acr17 @rheumnow #1801
— Janet (@Janetbirdope) November 8, 2017
Lots of different causes for Red Eye in autoimmune arthritis. Here’s a list #ACR17 @RheumNow pic.twitter.com/pMi2tLMDpk
— Dr Irwin Lim (@_connectedcare) November 8, 2017
Increased risk of CVA, but not for MI, in AS pts. #ACR17 @RheumNow #2972 https://t.co/5opG0IudgP pic.twitter.com/8PMXbJY7fq
— Dr. Rachel Tate (@uptoTate) November 8, 2017
#GAMECHANGER. Pts with early RA value pain control which is improving over recent years. #acr17 @rheumnow #2955 pic.twitter.com/PVPEqgavDY
— Janet (@Janetbirdope) November 8, 2017
RheumNow coverage of ACR17 Annual mtg is sponsored by Eli Lilly & Co. All content chosen by RheumNow Faculty https://t.co/WEPgNIaiaB
— Dr. John Cush (@RheumNow) November 8, 2017
Dr. Janet Pope: Therapy Effect on Radiographic Progression
RheumNow coverage of ACR 2017 meeting is sponsored by Horizon Pharmaceuticals.All content chosen by RheumNow Faculty https://t.co/Y6hSbkq72C
— Dr. John Cush (@RheumNow) November 8, 2017
Expanded RheumNow coverage of ACR 2017 meeting is sponsored by Eli Lilly & Co All content chosen by RheumNow Faculty https://t.co/GTs4mrumjt
— Dr. John Cush (@RheumNow) November 8, 2017
RheumNow coverage of ACR 2017 mtg is sponsored by Novartis. All content chosen by RheumNow Faculty https://t.co/TuKNHkz089
— Dr. John Cush (@RheumNow) November 8, 2017
RheumNow coverage of the ACR 2017 meeting is sponsored by Eli Lilly & Co. All content chosen by RheumNow Faculty https://t.co/AnVSXAaiCe
— Dr. John Cush (@RheumNow) November 8, 2017
Fibrosis/ILD included in proposed draft classification criteria for microscopic polyangiitis. #vasculitis #ACR17
— Alison Bays (@AlisonBays) November 8, 2017
Tim McAlindon talking on the relationship between telemore length and incident hand OA @TuftsMedicalCtr #ACR17 pic.twitter.com/BLEeKY1GrH
— Jeffrey Driban (@jbdriban) November 8, 2017
Think you know septic arthritis? Revolutionary insights from Ziv Paz. Come to 6D at 11am. #ACR17 pic.twitter.com/4kGScGQkjZ
— Jonathan Hausmann MD (@hausmannMD) November 8, 2017
Rheumatologists tackle empathy & mindfulness at #ACR17 @AOAforDOs @AACOMmunities @HealioRheum @RheumNow @boissyad https://t.co/8fTaQrqoax
— Leonard Calabrese (@LCalabreseDO) November 8, 2017
#ACR17 Rheumatology Roundup.Cush #11L biologics #2 CA; #1175 biologics infants; #141 Refractory RA; #1885 Epi of AOSD; #200 Gout Telemedicine ; #885 Voclosporin SLE GN. AKavanaugh #271 CD318; #1205 XRT OA? #661 Entheses; #1112 Pred Gout; #541 SIE; #2031 EMR labs; #144 MVA RA
— Dr. John Cush (@RheumNow) November 8, 2017
Artie Kavanaugh and @RheumNow highlighting the exciting aspects of #ACR17 pic.twitter.com/qgJZzxCIk3
— Philip Robinson (@philipcrobinson) November 8, 2017
Concepts of the different types of pain #ACR17 @RheumNow pic.twitter.com/ChyEw7vSvR
— Philip Robinson (@philipcrobinson) November 8, 2017
Sub-threshold fibromyalgia predicts non-response to surgery #ACR17 @RheumNow pic.twitter.com/AaDQBQbIVC
— Philip Robinson (@philipcrobinson) November 8, 2017
Continuum of pain from peripheral to central pain states in our rheumatology conditions #ACR17 @RheumNow pic.twitter.com/e03IMwec8o
— Philip Robinson (@philipcrobinson) November 8, 2017
Approaches to treat pain need to be guided by the type of pain you are trying to treat #ACR17 @RheumNow pic.twitter.com/a6NkvDTWUv
— Philip Robinson (@philipcrobinson) November 8, 2017
CNS amplification of the pain response #ACR17 @RheumNow pic.twitter.com/dgyi2aBMyc
— Philip Robinson (@philipcrobinson) November 8, 2017
Small fibre neuropathy – an important factor in fibromyalgia? #ACR17 @RheumNow pic.twitter.com/JaFgGTumAS
— Philip Robinson (@philipcrobinson) November 8, 2017
Higher non-painful sensory input in fibromyalgia patients “hyper-unpleasantness” #ACR17 @RheumNow pic.twitter.com/b0HB3MnTne
— Philip Robinson (@philipcrobinson) November 8, 2017
Cognitive processing abnormalities in fibromyalgia #ACR17 @RheumNow pic.twitter.com/xz3VuuVryS
— Philip Robinson (@philipcrobinson) November 8, 2017
There is rated-R material discussed. Log onto RheumNow under videos #ACR17 @rheumnow pic.twitter.com/BroSQi9Pdl
— k dao (@KDAO2011) November 7, 2017
US hypoechogenicity in 1 parotid + submandibular gland best predictor of ACR-EULAR class. #ACR17 @RheumNow #2903 https://t.co/10SvEZvGCK
— Dr. Rachel Tate (@uptoTate) November 8, 2017
Steroid tapering/discontinuation suggestions in JDM, ? best predictors of clinical remission. #ACR17 @RheumNow #2956 https://t.co/U7UQTD1hnj pic.twitter.com/shk6fOThlh
— Dr. Rachel Tate (@uptoTate) November 8, 2017
Joint synovial hypertrophy without Doppler activity improves during bDMARD suggesting active dz. #ACR17 @RheumNow https://t.co/OVIqGK6Hki
— Dr. Rachel Tate (@uptoTate) November 8, 2017
Provisional criteria for flare of global disease in cSLE pts. #ACR17 @RheumNow #2958 https://t.co/7v8SsOI2Hk pic.twitter.com/k5o6uUC0JG
— Dr. Rachel Tate (@uptoTate) November 8, 2017
So long San Diego and #ACR17! Check out our full coverage on https://t.co/xF1bNigE3C. See you in Chicago for more tweeting! @RheumNow pic.twitter.com/R5M3shmCgN
— Dr. Rachel Tate (@uptoTate) November 8, 2017